Cardiol Therapeutics 주식 (NASDAQ: CRDL)

Cardiol Therapeutics (NASDAQ:CRDL) 주식

Cardiol Therapeutics

Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.

Stocks.Watch_.Shutterstock

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

CRDL

ETWO

HELE

수요일 오전 (현지 시간 기준) 미국 주식 선물이 하락세를 보이면서 오늘 투자자들의 관심을 끌 수 있는 주식은 다음과 같다: 1. 월스트리트는 헬렌 오브 트로이(NASDAQ:HELE)가 개장 전에 분기 이익을 주당 1.04달러, 매출 4억 5824만 달러로 보고할 것으로 예상하고 있다. 헬렌 오브 트로이의 주식은 애프터 마켓에서 2.5% 상승한 63.93달러로 거래되었다.

수요일 주목해야 할 주식: 아즈, 헬렌 오브 트로이, 사라토가 그리고 2종목

Cardiol Therapeutics Inc. - Class A Common Shares

Cardiol Therapeutics Inc

Baird analyst Michael Ulz maintains Karyopharm Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPTI#NASDAQ">KPTI</a>) with a Outperform and lowers the price target from $54 to $42.

Price Target

Analyst Ratings

KPTI

Baird Maintains Outperform on Karyopharm Therapeutics, Lowers Price Target to $42

Needham analyst Ryan MacDonald reiterates Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) with a Buy and maintains $15 price target.

Reiteration

Needham Reiterates Buy on Evolent Health, Maintains $15 Price Target

Baird analyst Joel Beatty maintains Editas Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDIT#NASDAQ">EDIT</a>) with a Outperform and lowers the price target from $8 to $4.

EDIT

Baird Maintains Outperform on Editas Medicine, Lowers Price Target to $4

Honda Motor Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HMC#NYSE">HMC</a>) reported quarterly earnings of $0.18 per share. This is a 81.82 percent decrease over earnings of $0.99 per share from the same period last year. The company reported $35.15 billion in sales this quarter. This is a 3.94 percent decrease over sales of $36.59 billion the same period last year.

Honda Motor Co Q4 EPS $0.18 Down From $0.99 YoY, Sales $35.15B Down From $36.59B YoY

Baird analyst Joel Beatty maintains Dianthus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DNTH#NASDAQ">DNTH</a>) with a Outperform and lowers the price target from $58 to $50.

DNTH

Baird Maintains Outperform on Dianthus Therapeutics, Lowers Price Target to $50

Telsey Advisory Group analyst Cristina Fernandez maintains On Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONON#NYSE">ONON</a>) with a Outperform and maintains $65 price target.

ONON

Telsey Advisory Group Maintains Outperform on On Holding, Maintains $65 Price Target

HC Wainwright &amp; Co. analyst Matthew Caufield reiterates Mineralys Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLYS#NASDAQ">MLYS</a>) with a Buy and maintains $42 price target.

MLYS

HC Wainwright & Co. Reiterates Buy on Mineralys Therapeutics, Maintains $42 Price Target

Baird analyst Colleen Kusy maintains Agenus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGEN#NASDAQ">AGEN</a>) with a Neutral and raises the price target from $3 to $4.

AGEN

Baird Maintains Neutral on Agenus, Raises Price Target to $4

Jim Cramer believes that a consistent flow of trade agreements is crucial to bolstering market confidence and allaying fears of both recession and a surge in inflation.
What Happened: In a recent post on X, Cramer asserted that a &#8220;steady drip of trade deals&#8221; might be the key ingredient to sustain the current market momentum, particularly given the limited number of institutional investors holding bullish positions.
Cramer&#8217;s commentary underscores the market&#8217;s sensitivity to global trade dynamics and their potential impact on economic stability and price levels. The implication is that positive developments on the trade front could provide the necessary reassurance for investors, outweighing prevailing concerns about a potential economic downturn and escalating inflation.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Bulls, right now, want nothing but a steady drip of trade deals that will make people more confident that we won&#39;t have a recession and inflation won&#39;t spike. That might just be enough to keep things going given how few institutional bulls there are
&mdash; Jim Cramer (@jimcramer) <a href="https://twitter.com/jimcramer/status/1922199711055806937?ref_src=twsrc%5Etfw">May 13, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
In a subsequent post, Cramer also took aim at prominent bearish voices within the billionaire investor class. While not naming specific individuals in these recent posts, he emphasized the significant influence these figures wield and called for a change in their rhetoric. &#8220;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Last night i simply had to call out still one more bearish billionaire. I will tell you one thing, the words that are used by the billionaire class must change. They must learn their power for mayhem
&mdash; Jim Cramer (@jimcramer) <a href="https://twitter.com/jimcramer/status/1922199974479008140?ref_src=twsrc%5Etfw">May 13, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Cramer&#8217;s perspective suggests a delicate balancing act for the market. While positive trade developments could act as a vital catalyst for bullish sentiment and potentially ward off recessionary pressures, the pronouncements of influential bearish investors could introduce volatility and undermine confidence.
See Also: <a href="https://www.benzinga.com/government/regulations/25/05/45367206/sp-500-rallies-over-3-on-us-china-90-day-tariff-truce-but-experts-warn-it-doesnt-guarantee-a-complete-resolution-of-the-trade-war" target="_blank" rel="noreferrer noopener">S&amp;P 500 Rallies Over 3% On US-China 90-Day Tariff Truce, But Experts Warn It ‘Doesn't Guarantee A Complete Resolution Of The Trade War'</a>
Why It Matters: U.S. and China agreed on Monday to <a href="https://www.benzinga.com/markets/equities/25/05/45341884/apple-amazon-nvidia-rise-in-monday-premarket-as-us-china-agree-to-90-day-tariff-truce-neither-side-wants-a-decoupling">temporarily reduce reciprocal tariffs </a>on each other's goods for 90 days, marking a considerable easing of trade tensions. 
The recent tariff reductions between the <a href="https://www.benzinga.com/news/global/25/05/45337811/trump-announces-total-reset-as-us-china-trade-talks-aim-to-end-tariff-war">U.S. and China</a> echo a similar agreement reached with the U.K. last week, fueling optimism for a revival in global commerce and economic growth. 
However, Cramer&#8217;s call for steady progress on trade deals is vital, as the temporary nature of this 90-day deal with China doesn&#8217;t give a long-term solution.
Despite the initial positive action following the announcement, John Murillo, the chief dealing officer at B2BROKER, <a href="https://www.benzinga.com/government/regulations/25/05/45367206/sp-500-rallies-over-3-on-us-china-90-day-tariff-truce-but-experts-warn-it-doesnt-guarantee-a-complete-resolution-of-the-trade-war">emphasized</a>, "Now, while the 90-day pause is a big step towards easing tensions, it&#8217;s crucial to remember that it doesn&#8217;t guarantee a complete resolution of the trade war." 
Price Action: While the stocks rejoiced at the U.S.-China trade development on Monday, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, were lower in premarket on Tuesday. The SPY was down 0.22% to $581.70, while the QQQ declined 0.15% to $507.10, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data. The S&amp;P 500 futures were also trading lower on Tuesday morning.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45371290/chamath-palihapitiya-questions-ai-funding-after-swedish-bnpl-firm-klarna-rolls-back-ai-bets-startups-could-pivot-">Chamath Palihapitiya Says Swedish Fintech Company Klarna Scaling Back AI Support Is A Red Flag For Industry: Startups Could &#8216;Pivot To Simply Use AI For Narrow Use Cases&#8217;</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo: Shutterstock

Analyst Color

Equities

Government

Macro Economic Events

Macro Notification

Market Summary

Regulations

Broad U.S. Equity ETFs

Futures

Economics

ETFs

General

Jim Cramer Says Bulls Need 'Steady Drip Of Trade Deals' To Assure Market About Recession And Inflation As S&P 500 Futures Fall After Big Rally

AFMD

Trading Halt: Halted at 8:25:00 a.m. ET - Trading Halt: Halt News Pending

Baird analyst Joel Beatty upgrades argenx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARGX#NASDAQ">ARGX</a>) from Neutral to Outperform and maintains the price target from $680 to $680.

Upgrades

ARGX

Baird Upgrades argenx to Outperform, Maintains Price Target to $680

Earnings Beats

Earnings Misses

HUMA

UPDATE: Humacyte Q1 Adj. EPS $(0.10) Beats $(0.19) Estimate, Sales $517.00K Miss $760.33K Estimate

Mill City Ventures III (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCVT#NASDAQ">MCVT</a>) reported quarterly earnings of $0.07 per share. This is a 16.67 percent increase over earnings of $0.06 per share from the same period last year. The company reported $778.03 thousand in sales this quarter. This is a 6.56 percent decrease over sales of $832.67 thousand the same period last year.

MCVT

Mill City Ventures III Q1 GAAP EPS $0.07 Up From $0.06 YoY, Sales $778.03K Down From $832.67K YoY

Baird analyst Mircea Dobre upgrades Caterpillar (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>) from Neutral to Outperform and raises the price target from $309 to $395.

Baird Upgrades Caterpillar to Outperform, Raises Price Target to $395

LightInTheBox Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LITB#NYSE">LITB</a>) reported quarterly earnings of $0.01 per share. This is a 105.56 percent increase over losses of $(0.18) per share from the same period last year. The company reported $47.02 million in sales this quarter. This is a 33.93 percent decrease over sales of $71.17 million the same period last year.

LITB

LightInTheBox Holding Q1 EPS $0.01 Up From $(0.18) YoY, Sales $47.02M Down From $71.17M YoY

As of May 13, 2025, two stocks in the materials sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Crown Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCK#NYSE">CCK</a>)</h3>
<ul class="wp-block-list">
<li>On May 12, Crown Holdings reported that it has priced an offering of $700 million aggregate principal amount of 5.875% senior unsecured notes due 2033. The company's stock jumped around 14% over the past month and has a 52-week high of $99.12.</li>
<li>RSI Value: 72.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>CCK Price Action: Shares of Crown Holdings gained 0.8% to close at $97.78 on Monday.</li>
<li>Edge Stock Ratings: 78.55 Momentum score with Value at 29.80. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/quote/cck"><img loading="lazy" decoding="async" width="482" height="172" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13043838/image-137.png" alt="" class="wp-image-913115" style="width:390px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13043838/image-137.png 482w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13043838/image-137-300x107.png 300w" sizes="(max-width: 482px) 100vw, 482px" /></a></figure>
<h3 class="wp-block-heading">Celanese Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>)</h3>
<ul class="wp-block-list">
<li>On May 5, Celanese posted better-than-expected results for its first quarter. "Our end-markets in the first quarter exhibited dynamics similar to the fourth quarter, and demand in our businesses developed mostly as we expected," said Scott Richardson, president and chief executive officer. "While tariffs are a constant topic, we saw no direct impact in the first quarter. No matter how the demand environment develops over the remainder of the year, our mission is unchanged." The company's stock gained around 39% over the past month and <a href="https://www.benzinga.com/quote/CE">has a 52-week high</a> of $161.94.</li>
<li>RSI Value: 70.7</li>
<li>CE Price Action: Shares of Celanese gained 6.5% to close at $54.53 on Monday.</li>
</ul>
Curious about other BZ Edge Rankings? Click here to discover <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">how similar stocks measure up</a>. 
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/earnings/25/05/45368490/under-armour-cyberark-software-and-3-stocks-to-watch-heading-into-tuesday">Under Armour, CyberArk Software And 3 Stocks To Watch Heading Into Tuesday</a> </li>
</ul>
Photo via Shutterstock

Short Ideas

Top 2 Materials Stocks That May Keep You Up At Night In May

Baird analyst Mircea Dobre upgrades Terex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEX#NYSE">TEX</a>) from Neutral to Outperform and raises the price target from $48 to $66.

Baird Upgrades Terex to Outperform, Raises Price Target to $66

U.S. stock futures were lower this morning, with the Dow futures falling around 200 points on Tuesday.
Shares of 3D Systems Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DDD#NYSE">DDD</a>) fell sharply in today's pre-market trading after the company posted <a href="https://www.benzinga.com/quote/DDD/earnings">weaker-than-expected quarterly results.</a>
3D Systems reported quarterly losses of 21 cents per share which missed the analyst consensus estimate of losses of 14 cents per share. The company reported quarterly sales of $94.54 million which missed the analyst consensus estimate of $99.46 million.
3D Systems shares dipped 20.7% to $2.02 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul class="wp-block-list">
<li>Kearny Financial Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRNY#NASDAQ">KRNY</a>) shares dipped 23.5% to $5.00 in pre-market trading after gaining 3% on Monday.</li>
<li>Global IBO Group Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GIBO#NASDAQ">GIBO</a>) declined 18.8% to $4.22 in pre-market trading after dipping over 25% on Monday.</li>
<li>Kindly MD, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KDLY#NASDAQ">KDLY</a>) dipped 18.2% to $11.15 in pre-market trading. KindlyMD shares jumped 251% on Monday after the company announced a merger agreement with Nakamoto Holdings to start a Bitcoin treasury strategy.</li>
<li>Heritage Commerce Corp (NASDA: HTBK) declined 15.4% to $8.00 in pre-market trading.</li>
<li>Rigetti Computing Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>) fell 12.1% to $10.15 in pre-market trading after the company reported mixed first-quarter financial results.</li>
<li>Exodus Movement, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EXOD#NYSE">EXOD</a>) fell 11.1% to $48.25 in pre-market trading following first-quarter results.</li>
<li>NetClass Technology Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTCL#NASDAQ">NTCL</a>) dipped 11% to $25.80 in pre-market trading.</li>
<li>indie Semiconductor, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDI#NASDAQ">INDI</a>) declined 11% to $2.35 in pre-market trading after the company reported worse-than-expected quarterly sales results.</li>
<li>UnitedHealth Group Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) fell 9.1% to $344.44 in pre-market trading. The company announced the appointment of Stephen Hemsley as CEO.</li>
<li>Hertz Global Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTZ#NASDAQ">HTZ</a>) declined 8.6% to $6.34 in pre-market trading following weak quarterly results.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/earnings/25/05/45368490/under-armour-cyberark-software-and-3-stocks-to-watch-heading-into-tuesday">Under Armour, CyberArk Software And 3 Stocks To Watch Heading Into Tuesday</a> </li>
</ul>
Photo via Shutterstock

Movers

EXOD

GIBO

HTBK

INDI

KDLY

KRNY

NTCL

RGTI

3D Systems, Rigetti Computing, UnitedHealth Group And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Needham analyst Serge Belanger reiterates MoonLake (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLTX#NASDAQ">MLTX</a>) with a Buy and maintains $66 price target.

MLTX

Needham Reiterates Buy on MoonLake, Maintains $66 Price Target

Rosenblatt analyst Catharine Trebnick maintains Five9 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVN#NASDAQ">FIVN</a>) with a Buy and maintains $36 price target.

FIVN

Rosenblatt Maintains Buy on Five9, Maintains $36 Price Target

Press Releases

Thanksgiving Week Oversold Stocks to Watch: CRDL, QBTS, PRSO, RGTI & More!

"Market Movers: CTOR, CTNT, PNPN.V, KITT, SHIM – More Stocks Inside to Watch"

"Cardiol Therapeutics (NASDAQ: CRDL) Heart Health Innovation – AVCO, GXAI, UPC, and More Stocks Driving Groundbreaking Advances"

PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx™ Addressing Patients with Recurrent Pericarditis

Cardiol Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

Cardiol Therapeutics Announces Publication of Research in the Journal of the American College of Cardiology: Basic to Translational Science That Supports Development of Its Proprietary Subcutaneous Drug Candidate, CRD-38, for the Treatment of Heart Failure

Comments

Cardiol Therapeutics

뉴스

파트너 / 기고자

벤징가 글로벌